多模板元信息规范网络用于使用结构性MRI诊断阿尔茨海默病的诊断
IEEE transactions on medical imaging
|December 18, 2023
概括
这项研究引入了一个新的网络 (MMRN),通过更好地利用患者元数据来改善阿尔茨海默病的诊断. 该方法提高了诊断阿尔茨海默病的准确性,并预测轻度认知障碍进展.
科学领域:
- 神经成像是一种神经成像.
- 人工智能的人工智能
- 医学诊断 医学诊断 医学诊断
背景情况:
- 结构磁共振成像 (sMRI) 对阿尔茨海默病 (AD) 诊断至关重要,它提供了详细的体内脑形态测量.
- 现有的方法不足以解决元数据 (年龄,性别,教育) 对基于sMRI的AD诊断的复杂影响,导致潜在的混效应和偏见.
研究的目的:
- 开发一个新的多模板元信息规范化网络 (MMRN) 以实现更准确的计算机辅助阿尔茨海默病诊断.
- 有效地学习和解脱混的元数据从sMRI数据中的疾病相关特征.
主要方法:
- 在自我监督学习中使用多模板空间转换来增强数据.
- 整合弱监督的元信息学习和相互信息最小化,以规范诊断表示.
- 在大型阿尔茨海默病神经成像计划 (ADNI) 和国家阿尔茨海默病协调中心 (NACC) 队列上验证了MMRN.
主要成果:
- 在阿尔茨海默病的诊断中,MMRN显著超过了最先进的方法.
- 在预测轻度认知障碍 (MCI) 转化方面取得了卓越的表现.
- 在分类正常控制 (NC),MCI和AD阶段方面表现出高准确性.
结论:
- 拟议的MMRN有效地利用元数据来改善阿尔茨海默病的诊断和预测.
- 该方法能够解开混的元数据,这代表了基于神经成像的疾病诊断的重大进步.
更多相关视频
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
7.9K
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
14.9K
相关概念视频
Alzheimer's Disease: Overview
492
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
492
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
